Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abiomed, Inc. stock logo
ABMD
Abiomed
$381.02
$380.55
$219.85
$381.99
$17.18B1.4611,028 shs258 shs
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
$7.59
-1.8%
$7.01
$6.33
$8.38
$16.96B1.0755,736 shs29,067 shs
Insulet Co. stock logo
PODD
Insulet
$183.08
+3.8%
$169.73
$125.82
$331.65
$12.82B1841,101 shs453,379 shs
ResMed Inc. stock logo
RMD
ResMed
$216.57
-0.2%
$191.19
$132.24
$237.26
$31.82B0.641.06 million shs285,071 shs
Teleflex Incorporated stock logo
TFX
Teleflex
$203.00
+1.0%
$216.73
$177.63
$262.97
$9.56B1.13282,383 shs103,823 shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abiomed, Inc. stock logo
ABMD
Abiomed
0.00%0.00%0.00%0.00%0.00%
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
-1.81%+1.61%+11.95%+10.16%+8.43%
Insulet Co. stock logo
PODD
Insulet
+1.13%+3.61%+6.91%-11.64%-46.34%
ResMed Inc. stock logo
RMD
ResMed
-0.02%-0.05%+14.93%+13.75%-6.35%
Teleflex Incorporated stock logo
TFX
Teleflex
-1.01%-3.61%-7.29%-20.33%-22.09%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abiomed, Inc. stock logo
ABMD
Abiomed
N/AN/AN/AN/AN/AN/AN/AN/A
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
N/AN/AN/AN/AN/AN/AN/AN/A
Insulet Co. stock logo
PODD
Insulet
4.9358 of 5 stars
3.45.00.04.93.30.83.1
ResMed Inc. stock logo
RMD
ResMed
4.5673 of 5 stars
2.41.03.34.53.21.72.5
Teleflex Incorporated stock logo
TFX
Teleflex
4.9357 of 5 stars
3.35.01.73.92.52.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abiomed, Inc. stock logo
ABMD
Abiomed
N/AN/AN/AN/A
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
2.50
Moderate BuyN/AN/A
Insulet Co. stock logo
PODD
Insulet
2.80
Moderate Buy$240.3331.27% Upside
ResMed Inc. stock logo
RMD
ResMed
2.70
Moderate Buy$202.80-6.36% Downside
Teleflex Incorporated stock logo
TFX
Teleflex
2.67
Moderate Buy$261.7528.94% Upside

Current Analyst Ratings

Latest RMD, FSNUY, TFX, ABMD, and PODD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2024
Insulet Co. stock logo
PODD
Insulet
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$200.00
5/3/2024
Teleflex Incorporated stock logo
TFX
Teleflex
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$240.00 ➝ $219.00
5/3/2024
Teleflex Incorporated stock logo
TFX
Teleflex
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$205.00 ➝ $200.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$187.00 ➝ $200.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$227.00 ➝ $238.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$224.00 ➝ $236.00
4/1/2024
ResMed Inc. stock logo
RMD
ResMed
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$215.00 ➝ $224.00
3/27/2024
ResMed Inc. stock logo
RMD
ResMed
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$215.00
2/26/2024
Insulet Co. stock logo
PODD
Insulet
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$214.00 ➝ $213.00
2/23/2024
Insulet Co. stock logo
PODD
Insulet
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$250.00 ➝ $230.00
(Data available from 5/7/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abiomed, Inc. stock logo
ABMD
Abiomed
$1.03B16.65$5.09 per share74.88$33.03 per share11.54
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
$24.01B0.71$2.16 per share3.52$15.07 per share0.50
Insulet Co. stock logo
PODD
Insulet
$1.70B7.55$3.98 per share45.96$10.49 per share17.45
ResMed Inc. stock logo
RMD
ResMed
$4.22B7.53$7.79 per share27.79$28.11 per share7.70
Teleflex Incorporated stock logo
TFX
Teleflex
$2.97B3.21$18.83 per share10.78$94.49 per share2.15

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abiomed, Inc. stock logo
ABMD
Abiomed
$136.51M$5.8265.4769.783.3324.84%14.77%13.32%N/A
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
-$639.61M$0.1169.017.59N/A0.71%4.88%2.02%N/A
Insulet Co. stock logo
PODD
Insulet
$206.30M$2.9162.9147.313.1412.16%32.19%7.93%5/9/2024 (Confirmed)
ResMed Inc. stock logo
RMD
ResMed
$897.56M$6.5133.2725.242.6820.91%24.43%15.70%8/1/2024 (Estimated)
Teleflex Incorporated stock logo
TFX
Teleflex
$356.33M$6.2332.5813.361.959.82%14.78%8.79%8/1/2024 (Estimated)

Latest RMD, FSNUY, TFX, ABMD, and PODD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Insulet Co. stock logo
PODD
Insulet
$0.39N/A-$0.39N/AN/AN/A  
5/2/2024Q1 2024
Teleflex Incorporated stock logo
TFX
Teleflex
$3.07$3.21+$0.14$6.10$726.85 million$737.80 million      
4/25/2024Q3 24
ResMed Inc. stock logo
RMD
ResMed
$1.91$2.13+$0.22$2.22$1.17 billion$1.20 billion    
2/22/2024Q4 2023
Insulet Co. stock logo
PODD
Insulet
$0.67$1.40+$0.73$1.36$461.26 million$509.80 million    
2/22/2024Q4 23
Teleflex Incorporated stock logo
TFX
Teleflex
$3.26$3.38+$0.12$6.10$769.01 million$773.90 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abiomed, Inc. stock logo
ABMD
Abiomed
N/AN/AN/AN/AN/A
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
$0.172.24%N/A154.56%N/A
Insulet Co. stock logo
PODD
Insulet
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$1.920.89%+5.66%29.49%12 Years
Teleflex Incorporated stock logo
TFX
Teleflex
$1.360.67%N/A21.83%N/A

Latest RMD, FSNUY, TFX, ABMD, and PODD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2024
Teleflex Incorporated stock logo
TFX
Teleflex
Quarterly$0.340.68%5/14/20245/15/20246/14/2024
4/25/2024
ResMed Inc. stock logo
RMD
ResMed
Quarterly$0.480.88%5/8/20245/9/20246/13/2024
2/22/2024
Teleflex Incorporated stock logo
TFX
Teleflex
Quarterly$0.340.57%2/29/20243/1/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abiomed, Inc. stock logo
ABMD
Abiomed
N/A
7.93
7.17
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
0.36
1.54
1.44
Insulet Co. stock logo
PODD
Insulet
1.86
3.51
2.62
ResMed Inc. stock logo
RMD
ResMed
0.22
3.04
1.97
Teleflex Incorporated stock logo
TFX
Teleflex
0.37
2.51
1.41

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Abiomed, Inc. stock logo
ABMD
Abiomed
94.48%
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
N/A
Insulet Co. stock logo
PODD
Insulet
N/A
ResMed Inc. stock logo
RMD
ResMed
54.98%
Teleflex Incorporated stock logo
TFX
Teleflex
95.62%

Insider Ownership

CompanyInsider Ownership
Abiomed, Inc. stock logo
ABMD
Abiomed
2.50%
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
N/A
Insulet Co. stock logo
PODD
Insulet
0.47%
ResMed Inc. stock logo
RMD
ResMed
1.21%
Teleflex Incorporated stock logo
TFX
Teleflex
1.43%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Abiomed, Inc. stock logo
ABMD
Abiomed
2,00345.09 million43.96 millionOptionable
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
316,9202.23 billionN/ANot Optionable
Insulet Co. stock logo
PODD
Insulet
3,00070.02 million69.69 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
10,140146.91 million145.13 millionOptionable
Teleflex Incorporated stock logo
TFX
Teleflex
14,50047.10 million46.43 millionOptionable

RMD, FSNUY, TFX, ABMD, and PODD Headlines

SourceHeadline
Teleflex Incorporated (NYSE:TFX) Plans Quarterly Dividend of $0.34Teleflex Incorporated (NYSE:TFX) Plans Quarterly Dividend of $0.34
marketbeat.com - May 7 at 9:49 AM
Teleflex Incorporated (NYSE:TFX) Shares Acquired by Natixis Advisors L.P.Teleflex Incorporated (NYSE:TFX) Shares Acquired by Natixis Advisors L.P.
marketbeat.com - May 7 at 7:08 AM
Outcomes From Two New Head-to-Head Randomized Controlled Trials Involving the UroLift™ System Highlight a Superior Patient Experience* Against Rezūm and Its Advantage Over Medical Therapy as an Early Intervention for BPHOutcomes From Two New Head-to-Head Randomized Controlled Trials Involving the UroLift™ System Highlight a Superior Patient Experience* Against Rezūm and Its Advantage Over Medical Therapy as an Early Intervention for BPH
globenewswire.com - May 7 at 6:30 AM
Unlocking Teleflex (TFX) International Revenues: Trends, Surprises, and ProspectsUnlocking Teleflex (TFX) International Revenues: Trends, Surprises, and Prospects
zacks.com - May 6 at 2:56 PM
Teleflex: Compelling, Despite Some Operational HiccupsTeleflex: Compelling, Despite Some Operational Hiccups
seekingalpha.com - May 6 at 7:13 AM
Teleflex Announces Quarterly DividendTeleflex Announces Quarterly Dividend
globenewswire.com - May 6 at 6:30 AM
New York Life Investment Management LLC Increases Position in Teleflex Incorporated (NYSE:TFX)New York Life Investment Management LLC Increases Position in Teleflex Incorporated (NYSE:TFX)
marketbeat.com - May 6 at 6:08 AM
Teleflex (NYSE:TFX) Rating Reiterated by Needham & Company LLCTeleflex (NYSE:TFX) Rating Reiterated by Needham & Company LLC
americanbankingnews.com - May 5 at 6:46 AM
Teleflex (NYSE:TFX) Price Target Cut to $219.00Teleflex (NYSE:TFX) Price Target Cut to $219.00
americanbankingnews.com - May 5 at 3:46 AM
Teleflex (NYSE:TFX) Posts Quarterly  Earnings Results, Beats Expectations By $0.14 EPSTeleflex (NYSE:TFX) Posts Quarterly Earnings Results, Beats Expectations By $0.14 EPS
marketbeat.com - May 4 at 2:54 PM
Teleflex Incorporated (NYSE:TFX) Q1 2024 Earnings Call TranscriptTeleflex Incorporated (NYSE:TFX) Q1 2024 Earnings Call Transcript
finance.yahoo.com - May 3 at 9:01 PM
Teleflex (NYSE:TFX) Updates FY 2024 Earnings GuidanceTeleflex (NYSE:TFX) Updates FY 2024 Earnings Guidance
marketbeat.com - May 3 at 7:23 PM
Teleflex (TFX) Q1 Earnings Beat Estimates, Margins RiseTeleflex (TFX) Q1 Earnings Beat Estimates, Margins Rise
zacks.com - May 3 at 1:16 PM
Teleflex Inc (TFX) Q1 2024 Earnings Call Transcript Highlights: Strong Start with Revenue and ...Teleflex Inc (TFX) Q1 2024 Earnings Call Transcript Highlights: Strong Start with Revenue and ...
finance.yahoo.com - May 3 at 9:32 AM
Teleflex First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsTeleflex First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
finance.yahoo.com - May 3 at 9:32 AM
Teleflex (NYSE:TFX) PT Lowered to $219.00 at Truist FinancialTeleflex (NYSE:TFX) PT Lowered to $219.00 at Truist Financial
marketbeat.com - May 3 at 9:00 AM
Teleflexs (TFX) "Hold" Rating Reiterated at Needham & Company LLCTeleflex's (TFX) "Hold" Rating Reiterated at Needham & Company LLC
marketbeat.com - May 3 at 8:38 AM
How Is The Market Feeling About Teleflex?How Is The Market Feeling About Teleflex?
benzinga.com - May 2 at 4:05 PM
Teleflex beats quarterly profit estimates on healthy demand for medical devicesTeleflex beats quarterly profit estimates on healthy demand for medical devices
reuters.com - May 2 at 11:04 AM
Teleflex Q1 Results Top Estimates: Boosts FY24 Adj. EPS OutlookTeleflex Q1 Results Top Estimates: Boosts FY24 Adj. EPS Outlook
markets.businessinsider.com - May 2 at 11:04 AM
TFX Stock Earnings: Teleflex Beats EPS, Beats Revenue for Q1 2024TFX Stock Earnings: Teleflex Beats EPS, Beats Revenue for Q1 2024
msn.com - May 2 at 11:04 AM
Teleflex Inc (TFX) Q1 Earnings: Adjusted EPS Surpasses Estimates Amidst Revenue GrowthTeleflex Inc (TFX) Q1 Earnings: Adjusted EPS Surpasses Estimates Amidst Revenue Growth
finance.yahoo.com - May 2 at 11:04 AM
Teleflex (NYSE:TFX) Updates FY24 Earnings GuidanceTeleflex (NYSE:TFX) Updates FY24 Earnings Guidance
marketbeat.com - May 2 at 10:38 AM
Compared to Estimates, Teleflex (TFX) Q1 Earnings: A Look at Key MetricsCompared to Estimates, Teleflex (TFX) Q1 Earnings: A Look at Key Metrics
zacks.com - May 2 at 10:36 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Abiomed logo

Abiomed

NASDAQ:ABMD
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA

OTCMKTS:FSNUY
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Insulet logo

Insulet

NASDAQ:PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
ResMed logo

ResMed

NYSE:RMD
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.
Teleflex logo

Teleflex

NYSE:TFX
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.